Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
International Journal of Nanomedicine (Impact Factor: 4.2). 02/2012; 7:511-26. DOI: 10.2147/IJN.S24326
Source: PubMed

ABSTRACT Superparamagnetic iron oxide nanoparticles are attractive materials that have been widely used in medicine for drug delivery, diagnostic imaging, and therapeutic applications. In our study, superparamagnetic iron oxide nanoparticles and the anticancer drug, doxorubicin hydrochloride, were encapsulated into poly (D, L-lactic-co-glycolic acid) poly (ethylene glycol) (PLGA-PEG) nanoparticles for local treatment. The magnetic properties conferred by superparamagnetic iron oxide nanoparticles could help to maintain the nanoparticles in the joint with an external magnet.
A series of PLGA:PEG triblock copolymers were synthesized by ring-opening polymerization of D, L-lactide and glycolide with different molecular weights of polyethylene glycol (PEG(2000), PEG(3000), and PEG(4000)) as an initiator. The bulk properties of these copolymers were characterized using (1)H nuclear magnetic resonance spectroscopy, gel permeation chromatography, Fourier transform infrared spectroscopy, and differential scanning calorimetry. In addition, the resulting particles were characterized by x-ray powder diffraction, scanning electron microscopy, and vibrating sample magnetometry.
The doxorubicin encapsulation amount was reduced for PLGA:PEG(2000) and PLGA:PEG(3000) triblock copolymers, but increased to a great extent for PLGA:PEG(4000) triblock copolymer. This is due to the increased water uptake capacity of the blended triblock copolymer, which encapsulated more doxorubicin molecules into a swollen copolymer matrix. The drug encapsulation efficiency achieved for Fe(3)O(4) magnetic nanoparticles modified with PLGA:PEG(2000), PLGA:PEG(3000), and PLGA:PEG(4000) copolymers was 69.5%, 73%, and 78%, respectively, and the release kinetics were controlled. The in vitro cytotoxicity test showed that the Fe(3)O(4)-PLGA:PEG(4000) magnetic nanoparticles had no cytotoxicity and were biocompatible.
There is potential for use of these nanoparticles for biomedical application. Future work includes in vivo investigation of the targeting capability and effectiveness of these nanoparticles in the treatment of lung cancer.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Superparamagnetic iron oxide nanoparticles (SPION) have been widely used in medicine for magnetic resonance imaging, hyperthermia, and drug delivery applications. The effect of SPION on animal cells has been a controversial issue on which there are many contradictions. This study focused on preparation of SPION with novel biocompatible coatings, their characterization, and cytotoxicity evaluation. An amino acid (glycine) and two novel lipo-amino acids (2 amino-hexanoic acid and 2 amino-hexadecanoic acid) coated magnetic nanoparticles were characterized by various physicochemical means such as X-ray diffraction (XRD), transmission electron microscopy (TEM), vibrating sample magnetometry (VSM), differential scanning calorimetry (DSC), and infrared spectroscopy (FT-IR). The cytotoxicity profile of the synthesized nanoparticles on Hep-G2 cells as measured by MTT assay showed the nanoparticles are nontoxic and the cell growth is promoted by SPION. Moreover, lipoamino acid coating SPION appear more beneficial than the other ones. By increasing concentration of SPION, growth enhancing impact will attenuate and toxicity will appear. Although the aggregation of SPION can affect the results, the gradual delivery of ferric/ferrous ions into cells is the main cause of this growth promotion effect. Conclusively, this study shows that lipoamino acid coating SPION can be used for various biomedical purposes.
    Journal of Nanomaterials 04/2015; 2015(2015):9. DOI:10.1155/2015/451405 · 1.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is a major form of cancer, with a high mortality rate in women. It is crucial to achieve more efficient and safe anticancer drugs. Recent developments in medical nanotechnology have resulted in novel advances in cancer drug delivery. Cisplatin, doxorubicin, and 5-fluorouracil are three important anti-cancer drugs which have poor water-solubility. In this study, we used cisplatin, doxorubicin, and 5-fluorouracil-loaded polycaprolactone-polyethylene glycol (PCL-PEG) nanoparticles to improve the stability and solubility of molecules in drug delivery systems. The nanoparticles were prepared by a double emulsion method and characterized with Fourier Transform Infrared (FTIR) spectroscopy and Hydrogen-1 nuclear magnetic resonance (1HNMR). Cells were treated with equal concentrations of cisplatin, doxorubicin and 5-fluorouracil-loaded PCL-PEG nanoparticles, and free cisplatin, doxorubicin and 5-fluorouracil. The 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide (MTT) assay confirmed that cisplatin, doxorubicin, and 5-fluorouracil-loaded PCL-PEG nanoparticles enhanced cytotoxicity and drug delivery in T47D and MCF7 breast cancer cells. However, the IC50 value of doxorubicin was lower than the IC50 values of both cisplatin and 5-fluorouracil, where the difference was statistically considered significant (p˂0.05). However, the IC50 value of all drugs on T47D were lower than those on MCF7.
    02/2015; DOI:10.3109/21691401.2015.1008510
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Recent studies suggested that leptin as a mitogenic factor might play an important role in the process of initiation and progression of human cancer. Therefore, it could be considered as a target for breast cancer therapy. A previous study has showed that expression of leptin gene could be modulated by activation of estrogen receptors. Curcumin is a diferuloylmethane that has been shown to interfere with multiple cell signaling pathways and extensive research over the last 50 years has indicated this polyphenol can both prevent and treat cancer. Based on the fact that targeting of leptin could be considered as a novel strategy for breast cancer therapy, the aim of this study is the investigation of potentiality of curcumin for inhibition of leptin gene expression and secretion, and also, its link with expression of estrogen receptors. Methods Cytotoxic effect of curcumin on T47D breast cancer cells was investigated by MTT assay test after 24 and 48 treatments. Thereafter, the cells treated with different concentrations of curcumin. The levels of leptin, estrogen receptor α and estrogen receptor β genes expression was measured in the treated and control cells by Reverse-transcription real-time PCR. Amount of secreted leptin in the culture medium was also determined by ELISA in both treated and untreated cells. Finally data were statistically analyzed by one-way ANOVA test. Results Analysis of MTT assay data showed that curcumin inhibits growth of T47D cells with dose dependent manner. There were also significant difference between control and treated cells in the levels of leptin, estrogen receptor α expression levels and the quantity of secreted leptin that both were decreased in the treated cells compared with control cells. Conclusion Based on the results, curcumin inhibits the expression and secretion of leptin and it could probably be used as a drug candidate for the breast cancer therapy through the leptin targeting in the future.
    Cancer Cell International 12/2014; 14. DOI:10.1186/1475-2867-14-66 · 1.99 Impact Factor